SpaceDerivatives

$PRME Financials Deep Dive and Market Potential Thesis Prime Medicine is a company that has stood out as having a major potential not only for financial returns, but to the betterment of mankind. This is an absolute core of any investment I make because nothing is guaranteed when investing. If the investment were to fail, being able to hang your head high on the fact that you gave crucial liquidity to a company trying to improve human experience/life, you know that you attempted to push mankind forward in a tangible/meaningful way instead of just accepting the status quo. This is something you can be proud of even if you didn't meet your financial goals with the company. So many of us have/had loved ones that have been told they have incurable diseases that they have to live with or become a subscription model to mega pharmaceuticals, and I have too much faith in humanity that this is the best we can do. Let me start by saying that this is a high risk/high reward scenario with some competitors and is pushing against current behemoths in modern medicine, which in my mind, treats patients as a reoccurring cash cows that can negate, but not treat many diseases because they are unable or unwilling to. My initial company love was and is currently $RKLB. I found it as a diamond in the rough as a beaten down stock with a founder that was hell bent on delivering a better launch experience for small satellite companies so that a behemoth monopoly @SpaceX would not control the only keys to space at a time when government entities such as @NASA were faltering to deliver reasonable launch capabilities for the growing private sector. I cashed out my 401k, sold my car, and dropped every dime of liquidity I had into $RKLB and turned a $20k investment into nearly half million shortly after losing my job. I truly think $PRME is the next $3.50 to $35+ story in the making in the market that can benefit human health, as $RKLB is improving human exploration, communication, low/no gravity pharmaceutical development and so much more. I had people literally laugh in my face as would tell them the market potential of this small launch company, including family and friends. I never circled back for an "I told you so" only engaging with people asking me what's the next company that has the same potential as $RKLB? $PRME medicine has the same precursors as an early $RKLB (which I would highly recommend you check out if you haven't already). Two completely different arenas but very similar when you look under the hood as far as potential. $PRME has the potential to cure many diseases caused by genetic mutations like Cystic Fibrosis, Sickle Cell Disease, Huntington's Disease, Duchenne Muscular Dystrophy, and Hemophilia, Cancer, Diabetes, Alzheimer and so much more. While the proof of concepts are really focusing around Wilson's Disease and AATD (Alpha-1 Antitrypsin Deficiency) currently I see this as the tip of the iceberg that will snowball into all the areas mentioned above and including improving genetics on non-diseases, such as autism, and improving muscular, skeletal and integument (skin) conditions, allergy resistance and SO MUCH MORE. The market cap potential is in the tens to hundreds of billions by 2030. I am not a genetic scientist, but the multi-prong deletion/insertion, substitution, replacement, large deletion, large targeted insertion approach of $PRME on being able to do what $CRSP does but safer at a much more attractive market cap is highly enticing. Let's dive into whats under the financial hood shall we? That's why we are all here isn't it... For starters, a relatively low market cap of below 700m as of writing this. A very high short interest of 31.46% reported by fintel, including a off-exchange short volume of 39.64%. Why this is important is I love companies with huge potential that are largely shorted with relatively small market caps so that once the tide turns it can really move against those betting against them in a dramatic fashion ( $RKLB *cough cough* ) and a 8+ days to cover ratio, meaning if an unexpected update were to occur pushing the stock higher, it would take over 8 days to cover the squeeze, especially if it is gamma related (appreciation of calls on the stock). Who has a large stake backing the company? oh Alphabet company, the parent to $GOOGL owns 15m+ shares.. that's an interesting stake in a company that has a 94m public float 🤔👀 now what could they be doing with such a large stake in a genetic editing start up. Don't know, but I like it 😈 also $BMY having a 11m+ size position as of 10/24 is no data point to overlook either. Not to mention the obvious blocks owned by large institutions like Vanguard and BlackRock who own nearly 10m shares combined. This is pretty obvious, because they own everything that exists, but furthers the core ownership locked in by institutions. Arch Ventures Partners X and XII who buy disruptive scientific companies has a commanding stake they have only added to which appreciated to over 34m shares. Between Alphabet, Bristol Myers Squibb, BR, VG and Arch Ventures Partners own nearly 70m shares of a 178.2m total float company AND MANY MORE OWN MILLIONS OR TENS OF MILLIONS OF SHARES. Cash raise just occurred at the end of July/early August to securing delivery of operation runway for the near term foreseeable future. The CEO is laser focused on delivering on the two pipelines currently that are trying to leap from human testing to developing and procurement. After this occurs it can secure a portion if not majority of the pipeline for 40-50B TAM on Wilson's Disease and AATD which would secure funding for further development of new DNA editing on larger TAM improvements without need for further dilutive offerings. Now what happens when a company comes out with a permanent cure to a disease that is truly debilitating and under any current traditional medical trajectory would cost tens or hundreds of thousands of dollars for a side effect inhibitor/limiter? I would think that the company could charge astronomical fees in the hundreds of thousands or near millions for cures to these previously incurable diseases/genetic debilitations which I'm sure insurance would be responsible for a large portion of. This would be an insane cash generator for a company that can provide a permanent cure or prevention of millions of patients who would much prefer a permanent solution over a reoccurring subscription pharmaceutical or surgical subsidization. I have a fairly substantial stake in this company at this point with multiple hundreds of $4-$5 4/26 strikes that will only slam as new chains with further dates are added. THIS IS NOT FINANCIAL/INVESTMENT ADVICE PERFORM OWN DUE DILIGENCE/MARKET RESEARCH I will continue to elaborate on my thesis as my research and understanding develops. This is an initial dive into the company to pique interest and drive your own research.

The Hollow Men American capitalism is rotting from the head down. We have replaced the "Owner-Operator"—the risk-taker-with a new, parasitic class of corporate bureaucrat: The Risk-Free Insider. By "Insider," I am not referring to a specific title. I am referring to the entire administrative state that has captured the modern corporation. This includes the Directors who exist solely to collect fees, the Executives who exist solely to collect bonuses, and the Managers who exist solely to hire consultants. These are the hollow men of the boardroom. They are masters of PowerPoint. They wear the right suits. They say the right buzzwords about "governance" and "ESG." But they are mercenaries fighting a war with someone else’s ammunition. In a functioning economy, authority is tied to liability. If you make a bad decision, you lose your own money. That fear of loss is the only thing that keeps a business honest. It forces you to cut waste, obsess over the customer, and stay late to fix what is broken. Today, we have severed that link. We have rigged the game so that heads, the Insider wins; tails, the shareholder loses. If the stock goes up, the Insider collects a massive performance bonus. If the stock crashes due to their own incompetence, they are fired with a "Golden Parachute" worth tens of millions. They are gambling with the house’s money, and they never leave the table poorer than they arrived. This looting starts in the boardroom. We have normalized a "Country Club" culture where directors are selected based on social profiling rather than their ability to build a business. The modern board member is often a professional tourist—paid an average of $350,000 a year. Let’s be brutally honest about what that number represents. The average director is paid nearly five times the GDP per capita of the United States. They earn more for attending four quarterly lunches than the vast majority of Americans earn in five years of hard labor. And for what? Most of these directors are "over-boarded," sitting on three or four boards simultaneously. They treat directorships as a gig economy for the elite. They fly in, rubber-stamp a compensation package they didn't read, and fly out. They collect checks from companies they do not understand, do not use, and certainly do not love. They are not there to ask hard questions. They are there to be collegial. They are there to protect the other Insiders. And what happens when these boards hire executives who also have no personal capital at risk? We get the Delegation Economy. When a Risk-Free Insider faces a crisis—bloated expenses, a broken supply chain, or a stale product—they do not roll up their sleeves. They hire a consultant. They pay a strategy firm millions of shareholder dollars to produce a 100-page deck telling them what they already know. This is not management. It is intellectual money laundering. They use shareholder capital to buy an insurance policy for their own careers. If the plan fails, they can blame the consultants. They delegate the work because they are terrified of the responsibility. They would rather preside over a slow, comfortable decline than risk a bold mistake. While American Insiders are busy optimizing their severance packages, our global competitors are optimizing their products. They are not slowed down by bureaucracy. They are not waiting for a slide deck. They are outworking us. If we continue to fill our C-suites with administrators instead of operators, we will lose our edge. We will see iconic American franchises hollowed out by fees, managed for the benefit of the Insiders, while the true owners—the shareholders—are left holding the bag. The time for polite governance is over. If we want to save the American economy from mediocrity, we must demand a return to the "Owner’s Mentality." We need leaders who treat shareholder capital with the same reverence they treat their own savings. The era of the Risk-Free Insider must end.

I invested in the wrong $GME 😂

@saylor 11% will outperform every standard financial instrument.

Stretch your income to eleven. 11%. $STRC

@Ze1ooooo I’m reporting this

No days off No socks gang

@aytn4611 in $PRME but looking at $HIMS $NVO

@XFinancialX What biotech companies are you in? I was looking at some about 4 months ago but I never got into that sector

Even with horrible management $PYPL is too hard to ignore at this valuation. Still a monster in the P2P payment arena. New CEO, new opportunity to turn things around. Rounds my portfolio out of pure space, biotech and bitcoin.

@iamscarrr They were already cheap.. this is an OPPORTUNITY 😈

@XFinancialX Totally agree. These swing trades are going to be so juicy

$MSTR is not a bitcoin company. It’s a derivatives company. I don’t know everyone hyper fixates on where @saylor bought because you can make money in both directions of price movement. They win because of the heightened premium on the instruments beneath bitcoin.

To everyone that sold Bitcoin last week.

@Leo_Traydes Imagine this is the bottom stair on the way back to $400+ $mstr

Anyone stacking $MSTR at these prices? If you wholeheartedly believe in Bitcoin $MSTR is definitely worth a look 🤷‍♂️ Just imagine what numbers we see when it’s no longer a bear market for $BTC 👀

What a difference a day makes

@otium33 @GarciaCap

@XFinancialX @GarciaCap Yeah, people selling these bitcoin proxies near peak fear. I feel like it’s just bad timing.

I closed my positions in $TSLA $MSTR and $ASST on Wednesday morning This prevented a further drawdown of ~$28,000 Why? The vibes were off

@DeepValueBagger Half off from a few months ago is a great bargain if they are serious about a BSR. DCA at appropriate times as price slides can be advantageous instead of chasing ATH and recovering.

The Trump Administration should start buying Bitcoin for the Bitcoin Strategic Reserve. The current price is a bargain and the process will help stabilize the market and sell when the market runs up many years from now.

@XFinancialX 👀👀👀👀👀👀

Added $pypl $mstr $onds

Just got margin called for $4.1M, I don’t have extra money sitting around to cover this might get liquidated 😭 all my life savings are gone man.

@jrouldz It’s crazy to believe how relative those pre 4digits are! You buying or by proxy?

@XFinancialX that is the essence of a log chart my friend 😅 puts relative % move into perspective vs absolute dollar moves

$BTC 66K do not fade the logarithmic banana 🍌